Oral Curcumin Mitigates the Clinical and Neuropathologic Phenotype of the Trembler-J Mouse: A Potential Therapy for Inherited Neuropathy

Skre, 1974, Genetic and clinical aspects of Charcot-Marie-Tooth’s disease, Clin Genet, 6, 98, 10.1111/j.1399-0004.1974.tb00638.x Lupski, 2001, Charcoat-Marie-Tooth peripheral neuropathies and related disorders, 5759 Shy, 2005, Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features, 1623 Timmerman, 2006, 1 Lupski, 1991, DNA duplication associated with Charcot-Marie-Tooth disease type 1A, Cell, 66, 219, 10.1016/0092-8674(91)90613-4 Raeymaekers, 1991, Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group, Neuromuscul Disord, 1, 93, 10.1016/0960-8966(91)90055-W Lupski, 1992, Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A, Nat Genet, 1, 29, 10.1038/ng0492-29 Chance, 1993, DNA deletion associated with hereditary neuropathy with liability to pressure palsies, Cell, 72, 143, 10.1016/0092-8674(93)90058-X Chance, 1994, Two autosomal dominant neuropathies result from reciprocal DNA duplication/deletion of a region on chromosome 17, Hum Mol Genet, 3, 223, 10.1093/hmg/3.2.223 Lupski, 2005, Hereditary motor and sensory neuropathies involving altered dosage or mutation of PMP22: the CMT1A duplication and HNPP deletion, 1659 Pareek, 1993, Detection and processing of peripheral myelin protein PMP22 in cultured Schwann cells, J Biol Chem, 268, 10372, 10.1016/S0021-9258(18)82211-6 Snipes, 1992, Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13), J Cell Biol, 117, 225, 10.1083/jcb.117.1.225 Haney, 1996, Ultrastructural distribution of PMP22 in Charcot-Marie-Tooth disease type 1A, J Neuropathol Exp Neurol, 55, 290, 10.1097/00005072-199603000-00004 Martini, 1997, Animal models for inherited peripheral neuropathies, J Anat, 191, 321, 10.1046/j.1469-7580.1997.19130321.x Sereda, 2003, Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nat Med, 9, 1533, 10.1038/nm957 Passage, 2004, Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease, Nat Med, 10, 396, 10.1038/nm1023 Suter, 1992, A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the Trembler-J mouse, Proc Natl Acad Sci USA, 89, 4382, 10.1073/pnas.89.10.4382 Suter, 1992, Trembler mouse carries a point mutation in a myelin gene, Nature, 356, 241, 10.1038/356241a0 Isaacs, 2000, Identification of two new Pmp22 mouse mutants using large-scale mutagenesis and a novel rapid mapping strategy, Hum Mol Genet, 9, 1865, 10.1093/hmg/9.12.1865 Valentijn, 1992, Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A, Nat Genet, 2, 288, 10.1038/ng1292-288 Ionasescu, 1997, Dejerine-Sottas neuropathy in mother and son with same point mutation of PMP22 gene, Muscle Nerve, 20, 97, 10.1002/(SICI)1097-4598(199701)20:1<97::AID-MUS13>3.0.CO;2-Z Notterpek, 1997, Upregulation of the endosomal-lysosomal pathway in the trembler-J neuropathy, J Neurosci, 17, 4190, 10.1523/JNEUROSCI.17-11-04190.1997 Naef, 1999, Impaired intracellular trafficking is a common disease mechanism of PMP22 point mutations in peripheral neuropathies, Neurobiol Dis, 6, 1, 10.1006/nbdi.1998.0227 Colby, 2000, PMP22 carrying the Trembler or Trembler-J mutation is intracellularly retained in myelinating Schwann cells, Neurobiol Dis, 7, 561, 10.1006/nbdi.2000.0323 Fortun, 2006, Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression, Neurobiol Dis, 22, 153, 10.1016/j.nbd.2005.10.010 Egan, 2004, Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects, Science, 304, 600, 10.1126/science.1093941 Teijido, 2004, Localization and functional analyses of the MLC1 protein involved in megalencephalic leukoencephalopathy with subcortical cysts, Hum Mol Genet, 13, 2581, 10.1093/hmg/ddh291 Yang, 2005, Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo, J Biol Chem, 280, 5892, 10.1074/jbc.M404751200 Khajavi, 2005, Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants, Am J Hum Genet, 77, 841, 10.1086/497541 Dickson, 2002, Association of calnexin with mutant peripheral myelin protein-22 ex vivo: a basis for “gain-of-function” ER diseases, Proc Natl Acad Sci USA, 99, 9852, 10.1073/pnas.152621799 Kamholz, 1999, Regulation of myelin-specific gene expression: relevance to CMT1, Ann N Y Acad Sci, 883, 91, 10.1111/j.1749-6632.1999.tb08572.x Tomassini, 2004, Calnexin suppresses GD3 synthase-induced apoptosis, FASEB J, 18, 1553, 10.1096/fj.04-1675fje Cheng, 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, Anticancer Res, 21, 2895 Sancho, 2001, Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A, Brain, 124, 2177, 10.1093/brain/124.11.2177 Song, 2004, Evidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models, J Biol Chem, 279, 40629, 10.1074/jbc.M407308200 Price, 1988, Neurofilaments are spaced randomly in the radial dimension of axons, J Neurocytol, 17, 55, 10.1007/BF01735377 Starr, 1996, Neurofilament phosphorylation is modulated by myelination, J Neurosci Res, 44, 328, 10.1002/(SICI)1097-4547(19960515)44:4<328::AID-JNR3>3.0.CO;2-E Kobsar, 2005, Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A, J Neurosci Res, 81, 857, 10.1002/jnr.20601 Muchowski, 2005, Modulation of neurodegeneration by molecular chaperones, Nat Rev Neurosci, 6, 11, 10.1038/nrn1587 Lester, 2000, Gain of function mutants: ion channels and G protein-coupled receptors, Annu Rev Neurosci, 23, 89, 10.1146/annurev.neuro.23.1.89 Snipes, 1999, The anatomy and cell biology of peripheral myelin protein-22, Ann N Y Acad Sci, 883, 143, 10.1111/j.1749-6632.1999.tb08577.x Garriga, 2002, The eye photoreceptor protein rhodopsin: structural implications for retinal disease, FEBS Lett, 528, 17, 10.1016/S0014-5793(02)03241-6 Inoue, 2005, PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2, Neurogenetics, 6, 1, 10.1007/s10048-004-0207-y Bronstein, 2000, Function of tetraspan proteins in the myelin sheath, Curr Opin Neurobiol, 10, 552, 10.1016/S0959-4388(00)00125-2 Gow, 1998, Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease, J Cell Biol, 140, 925, 10.1083/jcb.140.4.925 Yang, 1996, Effect of organic acids in the prevention of aggregation on rapid refolding of proteins, Biochem Mol Biol Int, 38, 393 Sarkar, 2004, Cell signaling pathways altered by natural chemopreventive agents, Mutat Res, 555, 53, 10.1016/j.mrfmmm.2004.04.015